Belgian healthtech Azalea Vision has been selected for the European Innovation Council’s EIC Accelerator, which has identified up to €7.5 million in blended finance to move its smart contact lens platform from technical validation into clinical development. The proposed package includes a €2.5 million non-dilutive grant and a planned €5 million equity investment from the EIC Fund, intended to support clinical work, final engineering, and certification-facing development before the platform can become a regulated medical device. The company was the only Belgian business in the latest EIC Accelerator cohort, placing it among European deep-tech ventures selected for high-risk innovation support.
Funding and Program Context
Azalea’s announcement followed the EIC’s June 15 selection of 38 startups and small and medium-sized businesses from 16 EU and associated countries after the program’s evaluation process. The agency said the cohort is set to receive up to €90 million in grant support, while a further €202 million has been provisioned for potential equity investments, illustrating the program’s combination of public grants and risk capital. The EIC’s published project list also notes that selection does not constitute a final funding commitment until grant preparation is completed.
The Smart Lens Platform
Azalea says its lens-embedded system combines adaptive optics, custom microelectronics, liquid-crystal technology, and connectivity within a medical-grade contact lens architecture. The platform is designed to respond in real time to light, focus, and movement and is being developed for people living with irregular corneas, higher-order aberrations, and presbyopia. The company also sees an opportunity for tear-based biomarker monitoring, which could extend the platform beyond vision correction and light management into diagnostic applications over time.
Clinical Development Priorities
According to Azalea, core platform functionality has been established and technical validation is nearing completion, providing the basis for the next stage of development. The company plans to apply the EIC support to final engineering and clinical work, moving from technical validation toward clinical evaluation rather than a commercial launch. This approach aligns with the EIC Accelerator’s remit, which supports innovation activities at technology-readiness levels 6 to 8 and permits clinical trials within the grant component.
Company and Capital Strategy
Azalea Vision was founded in 2021 as a Ghent-based spin-off from imec and Ghent University, combining microelectronics and biomedical optics expertise. In 2025, the company announced the first €9 million closing of a planned €15 million Series A, intended to further develop its intelligent connected vision platform. It is now holding discussions with strategic and financial investors in Europe and the United States on potential co-investment alongside the EIC Fund and a future financing round.
The EIC Accelerator selection gives Azalea Vision public-sector backing at a stage when clinical evidence, safety, and performance will be central to its future. The funding is meant to bridge the gap between a technically validated smart lens and a medical device that can be evaluated in patients, although clinical proof, regulatory execution, and additional private capital will still determine its path to market. For Belgium’s deep-tech health ecosystem, the company’s inclusion in the latest cohort illustrates the importance of blended capital for hardware-intensive innovations with long development cycles and substantial upfront risk.